High-Throughput Alternative Splicing Detection In Patients With Non-Small Cell Lung Cancer Treated By Bevacizumab/erlotinib

被引：0
作者：
Baty, F. [1 ]
Brutsche, M. [1 ]
机构：
[1] Cantonal Hosp St Gallen, St Gallen, Switzerland
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2014年 / 189卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3476
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)
    Stinchcombe, T. E.
    Janne, P. A.
    Wang, X.
    Bertino, E. M.
    Weiss, J. M.
    Bazhenova, L.
    Gu, L.
    Lau, C. J.
    Paweletz, C. P.
    Jaslowski, A. J.
    Gerstner, G. J.
    Baggstrom, M. Q.
    Graziano, S. L.
    Beardenlii, J.
    Vokes, E. E.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 522 - 522
  • [22] Predictive value of serum MALDI-TOF proteomic profiling from patients treated with erlotinib and bevacizumab for survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib alone
    Dang, T. P.
    Salmon, J. S.
    Chen, H.
    Chen, S.
    Lee, J. W.
    Sandler, A. B.
    Herbst, R. S.
    Brahmer, J.
    Carbone, D. P.
    Shyr, Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [23] Skin rash as surrogate marker of efficacy in patients with non-small cell lung cancer treated with erlotinib
    Cobo, M.
    Cardenal, F.
    Insa, A.
    Domine, M.
    Lianes, P.
    Guillot, M.
    Montesinos, J.
    Bover, I.
    Amador, M. L.
    Paz-Ares, L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] Efficacy and Safety of Erlotinib in Previously Treated Advanced Non-Small Cell Lung Cancer
    Karaca, Halit
    Geredeli, Caglayan
    Kaplan, M. Ali
    Demirci, Umut
    Alici, Suleyman
    Artac, Mehmet
    Isikdogan, Abdurrahman
    Benekli, Mustafa
    Balakan, Ozan
    Arpaci, Erkan
    Budakoglu, Burcin
    Uncu, Dogan
    Guler, Tunc
    Berk, Veil
    Ozkan, Metin
    [J]. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2013, 23 (01): : 1 - 6
  • [25] ERLOTINIB AND BEXAROTENE FOR PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Dragnev, K. H.
    Seltzer, M.
    Rigas, J. R.
    DiSalvo, W. M.
    Simeone, S.
    Johnstone, D.
    Nugent, W.
    Waxman, S.
    Dmitrovsky, E.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 102 - 102
  • [26] Response to erlotinib and bevacizumab combination therapy after acquired resistance to osimertinib in patients with non-small cell lung cancer
    Satoh, Hiroaki
    Kagohashi, Katsunori
    [J]. ANTI-CANCER DRUGS, 2022, 33 (03) : 320 - 322
  • [27] Erlotinib and bevacizumab in chemotherapy-naive performance status 2 patients with advanced non-small cell lung cancer
    Al Baghdadi, T.
    Hanna, N.
    Bhatia, S.
    McClean, J.
    Johnson, C.
    Yu, M.
    Taber, D.
    Harb, W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Characterising acquired resistance to erlotinib in non-small cell lung cancer patients
    Karachaliou, Niki
    Codony-Servat, Jordi
    Paulina Bracht, Jillian Wilhelmina
    Ito, Masaoki
    Filipska, Martyna
    Pedraz, Carlos
    Chaib, Imane
    Bertran-Alamillo, Jordi
    Felipe Cardona, Andres
    Angel Molina, Miguel
    Rosell, Rafael
    [J]. EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (10) : 1019 - 1028
  • [29] A prospective cohort study of patients with non-squamous non-small cell lung cancer treated with bevacizumab
    Naoki, Katsuhiko
    Takeda, Yuichiro
    Soejima, Kenzo
    Arai, Daisuke
    Naka, Go
    Nagase, Seisuke
    Arirnura, Ken
    Kanemura, Toshinori
    Ohhira, Tatsuo
    Ikeda, Norihiko
    [J]. ONCOLOGY LETTERS, 2017, 13 (05) : 3285 - 3290
  • [30] A PROSPECTIVE COHORT STUDY OF NON-SQUAMOUS NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH BEVACIZUMAB
    Naoki, Katsuhiko
    Soejima, Kenzo
    Nagase, Seisuke
    Kanemura, Toshinori
    Ohhira, Tatsuo
    Takeda, Yuichiro
    Ikeda, Norihiko
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S868 - S868
12345